Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment Sanofi and Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. in the United States, have announced a collaboration to co-develop and co-commercialize asset TEV'574, which is currently in Phase ...
Find MoreFDA Approves AstraZeneca’s Imfinzi for Biliary Tract Cancer Imfinzi, a checkpoint inhibitor developed by AstraZeneca, has been approved by the FDA as the first immunotherapy for biliary tract cancer (BTC), a rare and aggressive form of cancer with few treatment options. Imfinzi (durvalumab) has been approved by ...
Find MorePsoriasis is a debilitating inflammation of skin affecting approximately 7.4 million adults in the United States. Recent researches demonstrating a surge in the Psoriasis prevalence indicating moderate-to-severe psoriasis, absence of safe, effective and easy to administer therapies has clearly resulted in several m...
Find MorePsoriasis is a skin inflammation which is a papulosquamous disease with variable morphology, distribution, severity, course, and duration.According to the WHO report 2016, studies on Psoriasis epidemiology have demonstrated varying prevalence rates across the globe (0.09–11.4%), with an apparent upward trend in sev...
Find MoreGeneralized pustular psoriasis (GPP) is a severe form of rare skin condition caused by abnormal inflammation. It is a type of psoriasis, which is characterized by long-lasting abnormal dry-skin patches all over the body. Bodies of the patients suffering from GPP develop red and tender skin covered with pus-fi...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.